Canrenoic Acid

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 412266

CAS#: 4138-96-9

Description: Canrenoic Acid is a synthetic pregnadiene derivative with anti-aldosterone activity.


Chemical Structure

img
Canrenoic Acid
CAS# 4138-96-9

Theoretical Analysis

MedKoo Cat#: 412266
Name: Canrenoic Acid
CAS#: 4138-96-9
Chemical Formula: C22H30O4
Exact Mass: 358.2144
Molecular Weight: 358.48
Elemental Analysis: C, 73.71; H, 8.44; O, 17.85

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Canrenoic Acid; EINECS223-963-0; EINECS-223-963-0; EINECS 223-963-0

IUPAC/Chemical Name: 3-((8R,9S,10R,13S,14S,17R)-17-hydroxy-10,13-dimethyl-3-oxo-2,3,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)propanoic acid

InChi Key: PBKZPPIHUVSDNM-WNHSNXHDSA-N

InChi Code: InChI=1S/C22H30O4/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21,26)12-8-19(24)25/h3-4,13,16-18,26H,5-12H2,1-2H3,(H,24,25)/t16-,17+,18+,20+,21+,22-/m1/s1

SMILES Code: C[C@]12CCC(C=C1C=C[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(CCC(O)=O)O)C)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 358.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Patinha D, Carvalho C, Persson P, Pihl L, Fasching A, Friederich-Persson M, O'Neill J, Palm F. Determinants of renal oxygen metabolism during low Na+ diet: effect of angiotensin II AT1 and aldosterone receptor blockade. J Physiol. 2020 Aug 28. doi: 10.1113/JP280481. Epub ahead of print. PMID: 32857872.

2: Nguyen VT, Farman N, Palacios-Ramirez R, Sbeih M, Behar-Cohen F, Aractingi S, Jaisser F. Cutaneous Wound Healing in Diabetic Mice Is Improved by Topical Mineralocorticoid Receptor Blockade. J Invest Dermatol. 2020 Jan;140(1):223-234.e7. doi: 10.1016/j.jid.2019.04.030. Epub 2019 Jul 3. PMID: 31278904.

3: Thuesen AD, Finsen SH, Rasmussen LL, Andersen DC, Jensen BL, Hansen PBL. Deficiency of T-type Ca2+ channels Cav3.1 and Cav3.2 has no effect on angiotensin II-induced hypertension but differential effect on plasma aldosterone in mice. Am J Physiol Renal Physiol. 2019 Aug 1;317(2):F254-F263. doi: 10.1152/ajprenal.00121.2018. Epub 2019 May 1. PMID: 31042060.

4: Bulluck H, Fröhlich GM, Nicholas JM, Mohdnazri S, Gamma R, Davies J, Sirker A, Mathur A, Blackman D, Garg P, Moon JC, Greenwood JP, Hausenloy DJ. Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial. Am Heart J. 2019 May;211:60-67. doi: 10.1016/j.ahj.2019.02.005. Epub 2019 Feb 20. PMID: 30893577; PMCID: PMC6483973.

5: Nakamura M, Eguchi A, Inohana M, Nagahara R, Murayama H, Kawashima M, Mizukami S, Koyanagi M, Hayashi SM, Maronpot RR, Shibutani M, Yoshida T. Differential impacts of mineralocorticoid receptor antagonist potassium canrenoate on liver and renal changes in high fat diet-mediated early hepatocarcinogenesis model rats. J Toxicol Sci. 2018;43(10):611-621. doi: 10.2131/jts.43.611. PMID: 30298849.

6: Pires PW, McClain JL, Hayoz SF, Dorrance AM. Mineralocorticoid receptor antagonism prevents obesity-induced cerebral artery remodeling and reduces white matter injury in rats. Microcirculation. 2018 Jul;25(5):e12460. doi: 10.1111/micc.12460. Epub 2018 Jun 7. PMID: 29758591; PMCID: PMC6117832.

7: Beygui F, Van Belle E, Ecollan P, Machecourt J, Hamm CW, Lopez De Sa E, Flather M, Verheugt FWA, Vicaut E, Zannad F, Pitt B, Montalescot G. Individual participant data analysis of two trials on aldosterone blockade in myocardial infarction. Heart. 2018 Nov;104(22):1843-1849. doi: 10.1136/heartjnl-2018-312950. Epub 2018 Apr 25. PMID: 29695512.

8: Dahmana N, Mugnier T, Gabriel D, Kaltsatos V, Bertaim T, Behar-Cohen F, Gurny R, Kalia YN. Topical Administration of Spironolactone-Loaded Nanomicelles Prevents Glucocorticoid-Induced Delayed Corneal Wound Healing in Rabbits. Mol Pharm. 2018 Mar 5;15(3):1192-1202. doi: 10.1021/acs.molpharmaceut.7b01028. Epub 2018 Feb 15. PMID: 29397733.

9: Zhao M, Rodríguez-Villagra E, Kowalczuk L, Le Normand M, Berdugo M, Levy- Boukris R, El Zaoui I, Kaufmann B, Gurny R, Bravo-Osuna I, Molina-Martínez IT, Herrero-Vanrell R, Behar-Cohen F. Tolerance of high and low amounts of PLGA microspheres loaded with mineralocorticoid receptor antagonist in retinal target site. J Control Release. 2017 Nov 28;266:187-197. doi: 10.1016/j.jconrel.2017.09.029. Epub 2017 Sep 22. PMID: 28947395.

10: Harvey AP, Montezano AC, Hood KY, Lopes RA, Rios F, Ceravolo G, Graham D, Touyz RM. Vascular dysfunction and fibrosis in stroke-prone spontaneously hypertensive rats: The aldosterone-mineralocorticoid receptor-Nox1 axis. Life Sci. 2017 Jun 15;179:110-119. doi: 10.1016/j.lfs.2017.05.002. Epub 2017 May 3. PMID: 28478264; PMCID: PMC5446265.

11: Chong C, Hamid A, Yao T, Garza AE, Pojoga LH, Adler GK, Romero JR, Williams GH. Regulation of aldosterone secretion by mineralocorticoid receptor-mediated signaling. J Endocrinol. 2017 Mar;232(3):525-534. doi: 10.1530/JOE-16-0452. Epub 2017 Jan 17. PMID: 28096435; PMCID: PMC5464000.

12: Sansoè G, Aragno M, Mastrocola R, Mengozzi G, Parola M. Alpha-2A Adrenoceptor Agonist Guanfacine Restores Diuretic Efficiency in Experimental Cirrhotic Ascites: Comparison with Clonidine. PLoS One. 2016 Jul 6;11(7):e0158486. doi: 10.1371/journal.pone.0158486. PMID: 27384184; PMCID: PMC4934922.

13: Beygui F, Cayla G, Roule V, Roubille F, Delarche N, Silvain J, Van Belle E, Belle L, Galinier M, Motreff P, Cornillet L, Collet JP, Furber A, Goldstein P, Ecollan P, Legallois D, Lebon A, Rousseau H, Machecourt J, Zannad F, Vicaut E, Montalescot G; ALBATROSS Investigators. Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical Trial. J Am Coll Cardiol. 2016 Apr 26;67(16):1917-27. doi: 10.1016/j.jacc.2016.02.033. PMID: 27102506.

14: Sansoè G, Aragno M, Mastrocola R, Parola M. Pathogenesis of solute-free water retention in experimental ascitic cirrhosis: is vasopressin the only culprit? Clin Sci (Lond). 2016 Jan;130(2):117-24. doi: 10.1042/CS20150479. Epub 2015 Oct 30. PMID: 26519424.

15: Alexandre J, Beygui F, Puddu PE, Manrique A, Rouet R, Milliez P. Electrophysiological and antiarrhythmic properties of potassium canrenoate during myocardial ischemia-reperfusion. J Cardiovasc Pharmacol Ther. 2015 May;20(3):313-21. doi: 10.1177/1074248414557036. Epub 2014 Nov 10. PMID: 25389106.

16: Iqbal J, Andrew R, Cruden NL, Kenyon CJ, Hughes KA, Newby DE, Hadoke PW, Walker BR. Displacement of cortisol from human heart by acute administration of a mineralocorticoid receptor antagonist. J Clin Endocrinol Metab. 2014 Mar;99(3):915-22. doi: 10.1210/jc.2013-2049. Epub 2013 Jan 1. PMID: 24423282; PMCID: PMC4392799.

17: Suyagh M, Hawwa AF, Collier PS, Millership JS, Kole P, Millar M, Shields MD, Halliday HL, McElnay JC. Potassium canrenoate treatment in paediatric patients: a population pharmacokinetic study using novel dried blood spot sampling. J Hypertens. 2013 Sep;31(9):1901-8. doi: 10.1097/HJH.0b013e3283626994. PMID: 23846862.

18: Feng X, Reini SA, Richards E, Wood CE, Keller-Wood M. Cortisol stimulates proliferation and apoptosis in the late gestation fetal heart: differential effects of mineralocorticoid and glucocorticoid receptors. Am J Physiol Regul Integr Comp Physiol. 2013 Aug 15;305(4):R343-50. doi: 10.1152/ajpregu.00112.2013. Epub 2013 Jun 19. PMID: 23785077; PMCID: PMC3833392.

19: Rademaker MT, Charles CJ, Nicholls MG, Richards AM. Interactions of enhanced urocortin 2 and mineralocorticoid receptor antagonism in experimental heart failure. Circ Heart Fail. 2013 Jul;6(4):825-32. doi: 10.1161/CIRCHEARTFAILURE.112.000205. Epub 2013 Jun 10. PMID: 23753530.

20: Rossi R, Crupi N, Coppi F, Monopoli D, Sgura F. Importance of the time of initiation of mineralocorticoid receptor antagonists on risk of mortality in patients with heart failure. J Renin Angiotensin Aldosterone Syst. 2015 Mar;16(1):119-25. doi: 10.1177/1470320313482603. Epub 2013 Mar 28. PMID: 23539659.



Additional Information

Canrenoic acid is a synthetic steroidal antimineralocorticoid which was never marketed.